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Amajor challenge in cartilage repair is the lack of chondrogenic cellsmigrating fromhealthy tissue into damaged areas and strategies
to promote this should be developed. The aim of this study was to evaluate the effect of peripheral blood derived mononuclear cell
(PBMC) stimulation onmesenchymal stromal cells (MSCs) derived from the infrapatellar fat pad of humanOAknee. Cellmigration
was measured using an xCELLigence electronic migration chamber system in combination with scratch assays. Gene expression
was quantified with stem cell PCR arrays and validated using quantitative real-time PCR (rtPCR). In bothmigration assays PBMCs
increased MSCmigration by comparison to control. In scratch assay the wound closure was 55% higher after 3 hours in the PBMC
stimulated test group (𝑃 = 0.002), migration rate was 9 times faster (𝑃 = 0.008), and total MSCmigration was 25 times higher after
24 hours (𝑃 = 0.014). Analysis of MSCs by PCR array demonstrated that PBMCs induced the upregulation of genes associated with
chondrogenic differentiation over 15-fold. In conclusion, PBMCs increase both MSC migration and differentiation suggesting that
they are an ideal candidate for inclusion in regenerative medicine therapies aimed at cartilage repair.
1. Introduction
Articular cartilage has limited reparative abilities and purely
chondral defects do not heal spontaneously. Progress of
degenerated tissue of the surrounding cartilage may lead to
osteoarthritis (OA) [1]. However, articular cartilage injuries
that penetrate the subchondral bone can undergo sponta-
neous repair through the formation of fibrocartilage [2].
Shapiro and coworkers [3] showed that this repair is medi-
ated by the proliferation and differentiation of mesenchy-
mal stromal cells (MSCs) that invade the defect from the
underlying bone marrow and vasculature. This physiological
repair response still forms the rationale behind a number of
orthopaedic procedures described as bone marrow stimula-
tion techniques [4].
Steadman et al. [5] first described the microfracture
procedure to enhance chondral resurfacing by introduc-
ing multiple holes below the articular cartilage defect into
the exposed subchondral bone plate. The healing capability
of this technique is based on the formation of a blood clot
and migration of cells from the bone marrow.The functional
long term outcome after microfracture surgery has presented
variable results, the main shortcomings including limited
hyaline repair tissue, variable repair cartilage volume, and
possibility of progressive ossification of the regenerated tissue
[6, 7].
Autologous cell implantation techniques have been devel-
oped [8] to overcome the degeneration of repair tissue.
However, finding an abundant source of healthy cells for cell
therapy remains a challenge [9–11]. The use of autologous
chondrocytes for cartilage repair strategies in older subjects
may be limited by both age-related and disease-associated
decline in chondrogenesis [12]. Currently, work on finding
viable alternatives to chondrocytes is increasing, particularly
as research on stem cell potential continues to grow [13–16].
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Although articular cartilage has poor repair ability,
increased joint remodeling with the formation of chondroos-
teophytes and loose bodies are common in OA suggesting
some potential for repair activity [17]. One possible explana-
tion for this could be that other tissue sources of suitable cells
are present within the joint. The reports by Jones et al. [18]
and English et al. [17] have documented multipotential and
chondrogenic MSCs in both OA synovial fluid (SF) and OA
Hoffa’s fad pad. Hoffa’s infrapatellar fat pad is situated under
and behind the patella within the knee and can be resected
with minimal morbidity [19]. Infrapatellar fat pad has been
shown to contain multipotential mesenchymal/stromal cells
that can be easily isolated and expanded in large numbers
retaining good chondrogenic capacity on extended passaging
[15, 17, 19–22].
Previous studies have shown that MSCs are systemically
or locally recruited to the site of injury in the early inflamma-
tory phase [23–25]. Low and inefficient homing of MSCs is
considered to be a major limitation of existing MSC-based
therapeutic approaches [26–28]. The mechanism by which
MSCs home to tissues and migrate across endothelium is
not yet fully understood. However, many of the molecules
known to be involved in the tethering, rolling, adhesion,
and transmigration of leukocytes from the bloodstream into
tissues are known to also be expressed on MSCs [29–31].
There is evidence that MSCs can respond to chemotactic
signaling molecules such as SDF-1/CXCR4 pathways [24],
monocyte chemotactic protein-3 (MCP-3) [30], and chemo-
tactic factors secreted by OA synovium and cartilage [32].
Chemokines are small, chemoattractant cytokines that play a
key role in the recruitment of leukocytes to sites of inflam-
mation and injury [33]. Many proinflammatory cytokines
are released from the injury site in the early inflammatory
phase [33, 34]. Growth factors and cytokines circulate in the
peripheral blood and reach articular cartilage through the
synovial fluid and several have been proposed as potential
chemoattractants in cartilage repair including FGF, PDGF,
VEGF, IGF-1, IL-8, BMP-4, BMP-7, TGF-𝛽, and SDF-1 [35,
36].
Peripheral blood cells are known to secrete circulat-
ing cytokines and therefore the authors hypothesized that
peripheral blood derived mononuclear cells (PBMCs) might
offer an easily available way to deliver these chemokines
therapeutically. The main aim of this study was to investigate
whether PBMCs can induce infrapatellar fat pad derived
MSC migration. Secondly, this study set out to evaluate the
effect of PBMC stimulation onMSC lineage commitment and
chondrogenic potential.
2. Materials and Methods
2.1. Infrapatellar Fat Pad Derived Mesenchymal Stem Cells.
Human tissue was obtained from patients undergoing total
joint replacement with full ethical consent (06/Q0108/213).
The size of the infrapatellar fat pad varied greatly between dif-
ferent patients. The infrapatellar fat pad was minced using a
sterile scalpel blade and placed in media containing 10% heat
inactivated FBS (fetal bovine serum), penicillin/streptomycin
(100 international units/mL and 100 𝜇g/mL), gentamycin
(10 ng/mL), and amphotericin B (2.5 𝜇g/mL).The average age
of seven consecutive donors was 71.4 ± 8.3 years with four
female and three male donors. The individual tissue samples
used in this study were obtained from separate donors at
different times and hence processed at different times.
The cells were released from the tissue by digesting with
collagenase A (11088793001, Roche) 0.2%w/v in complete
media for three hours on an orbital shaker at 37∘C. Once
digested, the cell suspensionwas strained through 100 𝜇mcell
strainers (Falcon) and centrifuged (400 g for 5 minutes) to
obtain a cell pellet. This pellet was washed twice in media
and the cells counted with a scepter 2.0 (Millipore) handheld
automated cell counter. For standard monolayer cultures, the
cells were plated on tissue culture plastic at a density of 20,000
cells/cm2 and cell passages 3–5 were used in the experiments.
2.2. Blood DerivedMononuclear Cells. Peripheral blood sam-
ples were taken from healthy volunteers with full ethical
consent using a sterile Monovette Starsted EDTA 9mL tube.
Peripheral blood mononuclear cell suspension was prepared
from fresh whole blood of 12 young (32.9 ± 9.3) healthy
volunteers (4 female and 8 male donors). Briefly, the blood
was diluted 1 : 1 with HBSS (without calcium or magnesium),
gently layered on LymphoPrep solution, and centrifuged for
20 minutes at 800 g. The mononuclear cell-rich band was
removed and resuspended in medium supplemented with
10% FBS and cells pelleted by centrifugation for 10 minutes
at 250 g [37].
2.3.Microenvironment. Standard cell culture conditions com-
prised a humidified atmosphere of 5% CO
2
in air inside
an incubator. In order to mimic the physiological oxygen
tension of hypoxic tissues, an environment comprising 90%
nitrogen, 5% oxygen, and 5% CO
2
was achieved using a
hypoxia chamber and controller unit (ProOx model C21,
BioSpherix, NY, USA) situated in a cell culture incubator.
Unless otherwise stated, the cultures were under normal
atmospheric oxygen tension (∼20%). All reagents used for
cell culture were purchased from Invitrogen unless otherwise
specified.
2.4. Cell Phenotyping. Flow cytometry was used to character-
ize CD90 and CD105 cell surface markers using CD90-FITC
Mouse IgG (IM1839U) and CD105-PE Mouse IgG (A07414,
Beckman Coulter). Additionally, CD34 (IM1870) and CD45
(A07782, Beckman Coulter) were used for negative selec-
tion. Fluorochrome-conjugated antibodies were incubated in
20𝜇L/2.0 × 105 cell suspension in full media or PBS for 20
minutes at room temperature protected from light. Finally the
cells were washed three times with PBS solution, resuspended
into IsoFlow Sheath Fluid (8546859, Beckman Coulter), and
the cell fluorescence was measured using Beckman Coulter
Cytomics FC500 instrument. The data was assessed with
Kaluza analysis software. Positivity for each antibody was
defined as the level of fluorescence >99% of the isotype-
matched control antibodies.
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2.5. Multilineage Analysis. Multilineage differentiation was
induced in this study with differentiation medium. MSCs
were cultured as a monolayer with 1.5 × 105 cells per well on
a 12-well plate for 21 days. After confluency, the cells were
treated with three differentiation media in triplicates with
basic media used as a negative control. At the end of the
experiment, the cells were fixed, stained, and analyzed under
a light microscopy.
For osteogenic differentiation [38–40] the medium con-
sisted of 50𝜇g/mL L-ascorbic acid 2-phosphate (A8960-5G,
Sigma), 10mM 𝛽-glycerol phosphate (G9422-10G, Sigma),
and 10 nM dexamethasone (50-02-2, Sigma). The medium
was changed every 3-4 days for over a period of 21 days. At
the end of the experiment, the osteogenic cultures were fixed
in 70% ethanol on ice for 1 hour and then stained with 2.0%
alizarin red solution for 10 minutes at room temperature and
finally washed three times with PBS.
To promote chondrogenic differentiation, StemPro
Chondrogenesis Supplement (A10064-10, Gibco, Paisley,
UK) was added to the basal medium and the medium was
changed every 3-4 days for over a period of 21 days [41].
Chondrogenic cultures were fixed with acetone/methanol
(1 : 1) at −20∘C for one minute before being stained with 0.5%
alcian blue (pH 0.75) overnight at room temperature and
washed three times with PBS.
For adipogenic differentiation, the StemProAdipogenesis
Supplement (A10065-01 Gibco, Paisley, UK) was added to the
StemPro basal media and the media was changed every 3-4
days over a period of 21 days. The adipogenic cultures were
fixed in 4% paraformaldehyde in PIPES buffer for 1 hour,
rinsed with DI water, and incubated with 60% isopropanol
for 5minutes at room temperature. Subsequently, the cultures
were stained with fresh oil red O solution (three parts 0.3% in
isopropanol with two parts water) for 5 minutes and washed
three times with PBS.
2.6. Migration Experiments
2.6.1. Scratch Assay. MSCs were grown to confluence in a 24-
well format and a thin “wound” (800 𝜇m) was introduced
by scratching the cell monolayer with a sterile pipette tip.
PBMCs were added to the culture (1 : 1) and the open gap was
inspectedmicroscopically over time as the cells moved in and
filled the damaged area. The migration of the cells from the
wound edge into the wound space was recorded using a time-
lapse imaging with Eclipse Ti Nikon and analyzed together
with Nikon Advanced Research Elements 3.21.00 software.
2.6.2. xCELLigence. The migration and chemoattractant
potential of the cells were measured using an xCELLigence
system RTCA DP real-time cell analyzer fitted with CIM
plates (05665817001, Roche). The CIM plates have 16-well
migration chambers comprising upper and lower chambers
separated by a porous (pore size 8 𝜇m) polyethylene tereph-
thalate (PET) membrane in conjunction with microelec-
trodes. The lower chamber of a 16-well CIM plate was filled
with cell culture medium, whilst the upper chamber was
seeded with 2.0 × 104 cells in medium. In the xCELLigence
assay, three test groups were used; (1) MSCs in the upper
chamber alonewith PBMCs (1 : 1) in the lower chamber to test
directed cellmovementwithout cell-to-cell contact, (2)MSCs
in the upper chamber alone and 1% FBS as a negative control
in the lower chamber, and (3) PBMCs in the upper chamber
alone and 1% FBS as a second negative control in the lower
chamber. After equilibration, the analyzer was programmed
to scan the membrane every 15 minutes for the first 24 hours
and thereafter once an hour.
2.7. mRNA Expression. Mesenchymal stromal cells were cul-
tured with or without PBMCs (1 : 1) for 24 hours. After
the stimulation, the PBMCs were washed away to avoid
mRNA from the mononuclear cells grown in suspension.
MSC mRNA was extracted using the TRIzol reagent (15596-
026, Ambion) according to manufacturer’s instructions.
The RNA pellet was air-dried and resuspended into 35 𝜇L
DNAse/RNAse-free water; subsequently, concentration and
quality were checked with OD 260/280 measurement using
a NanoDrop spectrophotometer. Quality was verified by
agarose 1.2% gel electrophoresis using FlashGel system
(57067, Lonza, US) and RNA cassettes (57027, Lonza, US).
2.7.1. PCR Array. cDNA synthesis was performed with RT2
first strand kit (330401, Qiagen). For each reaction, 2.8 𝜇g
RNA was mixed with 2 𝜇L 5X gDNA elimination buffer,
incubated for 5min at 42∘C and chilled on ice. Subsequently,
4 𝜇L 5X Reverse transcription buffer, 2 𝜇L RT enzyme mix
reverse transcriptase mix, 1𝜇L primer and external control
mix, and RNAse-free water were added to make a final
volume of 10 𝜇L. Reverse transcriptase cocktail and genomic
DNA elimination mixture were combined 1 : 1, mixed gently,
and incubated for 15 minutes at 42∘C, and then immediately
the reaction was stopped by heating for 5 minutes at 95∘C.
Human mesenchymal stem cell PCR array RT2 profiler
(PAHS-082Z, Qiagen) and human stem cell RT2 profiler PCR
array (PAHS-405, Qiagen) were used to identify and compare
84 key genes on each array. A Stratagene Mx3000P real-time
cycler was programmed with HotStart DNA Taq Polymerase
activation for 10 minutes at 95∘C and then 40 cycles of
(1) denaturation for 15 s at 95∘C and (2) combined anneal-
ing/extension for 1 minute at 60∘C. The data acquisition was
performed during the combined annealing/extension step
and the results were analyzed with RT2 Profiler PCR array
data analysis software version 3.5 using the ΔΔCt method
and normalized to the mean of five housekeeping genes used
(B2M, HPRT1, RPL13A, GAPDH, and ACTB).
2.7.2. Quantitative rtPCR. The cDNA synthesis was per-
formed with SuperScript VILO kit (11754-050, Invitrogen).
For each reaction, up to 2.5𝜇g RNA was mixed with 4 𝜇L
VILO reaction mix, 2 𝜇L 10X SuperScript enzyme, and
DEPC-treated water added until to a total of 20 𝜇L. The
reaction mixture was incubated for 10 minutes at 25∘C
and then 60 minutes at 42∘C and finally the reaction was
terminated with 5 minutes at 85∘C.
The real-time quantitative PCR reaction was prepared
using QuantiFast SYBR Green (204054, Qiagen). A total
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volume of 25 𝜇L of reaction was prepared with 12.5 𝜇L 2x
QuantiFast SYBR Green PCR Master Mix, 2.5 𝜇L Quan-
tiTect Primer Assay (Hs BMP2 1 SG, Hs BMP6 1 SG, Hs
GDF5 1 SG, Hs GDF6 1 SG, and Hs SOX9 1 SG), 50 ng
template cDNA, and RNase-free water. Stratagene Mx3000P
real-time cycler was programmed with an initial heat acti-
vation for 5min at 95∘C followed by a 2-step cycling; firstly
denaturation for 10 s at 95∘C, followed by a combined anneal-
ing/extension for 30 s at 60∘C, repeated for 40 cycles. The
data acquisition was performed during the combined anneal-
ing/extension step. The relative copy numbers of target genes
were calculated from the standard curve for each gene and
normalized to the housekeeping gene beta-2 microglobulin
(B2M).
2.8. Data Analysis. All samples were collected in four repli-
cates and the data is presented as the mean ± standard
deviation (SD). The data were evaluated using Student’s 𝑡-
test to determine statistically significant differences with
GraphPad Prism 5 software package. All data were confirmed
for normal distribution with the significance level set at 0.05.
3. Results
3.1. MSC Characterization. Adipose tissue-derived MSCs
isolated from the infrapatellar fat pad presented CD90 and
CD105 cell surface markers typical of an MSC phenotype
lacking the CD34/45 expression (measured at passage 4).
Hypoxic culture environment similar to that of native car-
tilage tissue did not have significant effect on MSC pro-
genitor cell population (95.7 ± 3.3% CD90/CD105 positive)
when compared to the normoxic culture (84.1 ± 17.0%
CD90/CD105 positive) (𝑃 = 0.07, Figure 1(a)) although there
was a beneficial trend.
Staining of MSCs after 21 days in differentiation media
showed that the resultant cells displayed phenotypic charac-
teristics of osteogenic, chondrogenic, and adipogenic path-
ways in vitro (Figure 1(b)). Osteogenic differentiation of
cultured cells formed mineralizing aggregates that stained
with an alizarin red. The characteristic accumulation of
matrix in chondrogenesis was observed with an alcian blue
staining of developing chondrogenic pellets. Adipogenesis
was indicated by the accumulation of neutral lipid vacuoles
that stained with an oil red O staining. Low oxygen tension
was not found to reduce the differentiation potential ofMSCs.
Therefore, the functional differentiation assay demonstrated
that the multipotent differentiation capability of MSCs was
independent of oxygen tension.
3.2. Evaluating MSC/PBMC Coculture
3.2.1. Cell Migration. Scratch assay showed that direct cell-
to-cell PBMC stimulation increased the wound closure rate
by 55.2% at 3 hours, 𝑃 = 0.002 (Figure 2(a)). The distance
of the gap was measured at 12-, 15-, and 24-hour time points
(Figure 2(b)) and every time point the PBMC treated wound
had smaller scratch area (𝑃 < 0.0001). To confirm the
findings from the scratch assay and to assess if direct cell-
to-cell contact is needed for the chemotactic effect, a second
assay based on the Boyden chamber model (xCELLigence)
was used to quantify cell migration. The real-time cell
migration assay demonstrated that during the first 3 hours the
MSC migration was 9 times faster in the PBMC stimulated
test group (𝑃 = 0.008, Figure 2(c)). The results of the 24-
hour migration assay show that in vitro MSC migration was
25 times higher when stimulatedwith the PBMCs (𝑃 = 0.014,
Figure 2(d)) even though the cells did not have direct cell-
to-cell contact. The directed migration was not found in the
negative controls.
3.2.2. mRNA Expression. In total the expressions of 158 genes
related to stem cell differentiation, growth, pluripotency,
self-renewal, and the mesenchymal lineage commitment
pathways were measured using a commercial array. In total
mRNA levels of 52 genes involved in MSC differentiation
and growth were upregulated by the PBMC stimulation as
compared to the unstimulated test group. Stemness marker
mRNA levels for FGF2, INS, LIF, SOX2, TERT, WNT3A, and
ZFP42 were upregulated (>15-fold) by PBMC stimulation.
The mRNA levels of 19 genes specific to MSCs (ALCAM,
ANPEP, BMP2, CASP3, CD44, ENG, ERBB2 (HER2),
FUT4, FZD9, ITGA6, ITGAV, KDR, MCAM, NGFR, NT5E,
PDGFRB, PROM1, THY1, and VCAM1) were also upregu-
lated in PBMC stimulated MSCs. A partial effect was seen on
the mRNA levels of 11 genes specific to osteogenesis, where
7 of them (BMP2, BMP6, FGF10, HNF1A, KDR, RUNX2,
and TBX5) were upregulated by 24-hour PBMC stimulation.
Messenger-RNA levels for 8 genes coding ABCB1, BMP2,
BMP6, GDF5, GDF6, GDF7, ITGAX, and SOX9 proteins
specific to chondrogenic differentiation were upregulated by
over 15-fold following PBMC stimulation. Real-time PCRwas
used to further investigate five key chondrogenic genes and
the results confirm that mRNA levels for all these genes were
upregulated by the PBMCs (Figure 3(c): BMP2, BMP6 (𝑃 =
0.049), GDF5, GDF6 (𝑃 = 0.028), and Sox9 (𝑃 = 0.043)).
4. Conclusions
A major issue in cartilage repair is the lack of chondrogenic
cells migrating from healthy tissue into damaged areas whilst
maintaining their phenotype. In addition, unlike themajority
of tissues, cartilage healing does not involve mononuclear
cells as it is essentially avascular. To our knowledge, no
previous publications have reported the use of PBMCs as a
source of chemoattractants in cartilage tissue repair.Our aims
in this study were to establish whether PBMCs had a positive
influence on MSC migration and phenotype.
In both scratch assay and real-time Boyden chamber
analysis, PBMCs were found to stimulate MSC migration.
The addition of PBMCs was found to increase the MSC
cell migration rate by 55% at the 3-hour time point (𝑃 =
0.002) in a scratch assay with direct cell-to-cell contact. The
Boyden chamber real-time cell migration assay confirmed
that during the first 3 hours the MSC migration rate was 9
times faster in the PBMC stimulated test group (𝑃 = 0.008)
compared to nonstimulated one. The results of the 36-hour
migration assay show that in vitroMSC migration rose to 25
times higher when stimulated with the PBMCs (𝑃 = 0.014).
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Figure 1: (a) Flow cytometry result of CD90 and CD105 expression in human primary MSCs (𝑛 = 6) both normoxia and hypoxia. Results
are expressed as mean % of positive cells in the whole population. (b) Multidifferentiation assay for osteogenic (alizarin red), chondrogenic
(alcian blue), and adipogenic (oil red O) staining of MSC cultures in both normoxia and hypoxia at day 21 (scale bar 200 nm, 𝑛 = 4).
These results clearly demonstrate that PBMCs can induce
MSC motility and increase both the total number of cell
migration as well as the rate of cell movement. Additionally,
the xCELLigence assay showed that no direct cell-to-cell
contact was required as the directed cell movement was
observed when MSCs were in the upper chamber separated
from the PBMCs in the lower chamber. The migration of
MSCs is known to be regulated by a variety of cytokines,
such as FGF-2, PDGF, and MIF [42–45]. Among the PBMC
released cytokines, one possible candidate for future study
is monocyte chemoattractant protein 1 (MCP-1) as it has
been shown to mediate migration of MSCs in a rat aortic-
allograftmodel [46]. Future work should investigate the indi-
vidual chemotactic factor or factors present in heterogeneous
PBMCs in order to harness the full potential of the directed
cell migration property.
Physiologically the infrapatellar fat pad is found in
close vicinity to articular cartilage in the knee making it a
prospective tissue type to recruit stem cells for tissue repair
[19]. In our study, MSCs derived from the infrapatellar fat
pad at passage three were over 84% positive for the MSC
markers and this could be even further induced to over 96%
by using hypoxic cell culture conditions.This is an important
finding and warrants future studies to evaluate the biological
mechanism by which hypoxia appears to either support or
select (selective cell survival) the progenitor cell phenotype.
The multidifferentiation potential of infrapatellar fat pad
derived progenitor cells was confirmed with a functional
assay showing that when cultured in an appropriate cell
culture environment, the cells displayed many of the pheno-
typic characteristics of cells of the osteogenic, chondrogenic,
and adipogenic lineages. Unlike previous studies [47, 48],
hypoxic culture conditions did not improve the chondrogenic
differentiation capability of MSCs in this current study.
Successful hypoxic preconditioning may be related to the
timing of hypoxia as this appears to have an important
function early in the lineage progression, modulating colony
formation and proliferation. The fact that hypoxia did not
reduce the differentiation potential of MSCs in our model is
encouraging and allows infrapatellar fat pad derived MSCs
to be considered as a viable candidate to become a suitable
cell source in therapeutic cartilage repair. Further research is
needed to elucidate the biological effect of low oxygen tension
on infrapatellar fat pad-derived progenitor cell types.
Since no studies have reported the use of MSCs together
with PBMCs, this study serves as the original basis to evaluate
this coculture model.The human stem cell andmesenchymal
stem cell PCR array results showed that humanMSCs derived
from infrapatellar fat pad expressed keymarkers for cell cycle
regulators, chromosome and chromatin modulators, genes
regulating symmetric/asymmetric cell division, self-renewal
markers, and cell adhesion molecules as well as signaling
pathways important for stem cell maintenance including the
Notch- and Wnt-pathways. MSCs expressed mesenchymal
lineage markers but lacked the expression for embryonic and
hematopoietic cell lineage markers (Ct > 35, data not shown).
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Figure 2: Cell migration experiment of MSCs measured over 24 hours comparing the effect of PBMC stimulus (𝑛 = 4). (a) Wound closure
rate measured at 3-hour time point (𝑛 = 4) in the scratch assay with direct cell-to-cell contact. (b) The total distance of the wound measured
at 12-, 15-, and 24-hour time points is not to scale (𝑛 = 4, 𝑃 < 0.0001) in the scratch assay. (c) The initial cell migration rate at 3-hour time
point quantified real time with the xCELLigence system and (d) the total amount of cells migrated at the 24-hour time point quantified with
cell index value by xCELLigence.
The 24-hour PBMC stimulation produced an increase in
mRNA levels for 52 genes related to mesenchymal lineage
commitment. Seven genes of these are known to be key in
control of the stemness of themesenchymal stem cells (FGF2,
INS, LIF, SOX2, TERT, WNT3A, and ZFP42).
The ability of adipose-derived stem cells to undergo
chondrogenic differentiation has been studied extensively,
and it has been suggested that the most promising growth
factors for chondrogenesis appear to be TGFbeta-3 and bone
morphogenetic protein- (BMP-) 6 [49], both of which gene
transcripts were upregulated by the PBMCstimulation on our
study. The MSC specific PCR array in this paper confirms
the presence of MSC-specific markers and provides evidence
that infrapatellar fat pad derived stem cells can express
differentiation markers for osteogenic and chondrogenic
lineages and, moreover, PBMCs can further stimulate the
expression of differentiation markers. Eight genes associated
with chondrogenic differentiation (ABCB1, BMP2, BMP6,
GDF5, GDF6, GDF7, ITGAX, and SOX9) were upregulated
by over 15-fold by the PBMC stimulation. This positive find-
ing was confirmed using qPCR with five key chondrogenic
genes (BMP2, BMP6 (𝑃 = 0.049), GDF5, GDF6 (𝑃 = 0.028),
and Sox9 (𝑃 = 0.043)) demonstrating that PBMCs have a
positive reparative influence on MSCs in cartilage.
Taken together, this study presents a readily available
source of cells from the peripheral blood to supportmigration
and chondrogenic differentiation of mesenchymal stromal
cells from the infrapatellar fat pad in the knee. The ability
to considerably enhance regeneration of functional cartilage
from adult human mesenchymal stromal cells would have
tremendous clinical impact. Other studies are currently
under way using a large animal model to examine the
therapeutic benefits of these cells to repair articular surface
and osteochondral defects.
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Figure 3: Change in mRNA levels after 24 h PBMC stimulation with a cut-off value of 4. (a) A scatter plot showing up- and downregulated
genes and core genes with no change (𝑛 = 1). (b) A heat map visualization of 2log2-fold change of the 84 genes in the stem cell PCR array (red:
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